Ken Griffin Procept Bio Robotics Corp Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 32,800 shares of PRCT stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,800

Previous 26,800 22.39%

Holding current value

$2.22 Million

Previous $2.15 Million 23.07%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$67.27 - $99.45 $2.06 Million - $3.04 Million	30,561 Added 70.07%	74,178 $5.97 Million
Q3 2024 Nov 14, 2024	BUY	$56.31 - $84.99 $913,179 - $1.38 Million	16,217 Added 59.19%	43,617 $3.49 Million
Q2 2024 Aug 14, 2024	BUY	$45.73 - $69.19 $419,618 - $634,887	9,176 Added 50.35%	27,400 $1.67 Million
Q1 2024 May 15, 2024	SELL	$40.38 - $50.75 $9.59 Million - $12.1 Million	-237,483 Reduced 92.87%	18,224 $900,000
Q4 2023 Feb 14, 2024	SELL	$24.89 - $43.41 $21.4 Million - $37.3 Million	-858,580 Reduced 77.05%	255,707 $10.7 Million
Q3 2023 Nov 14, 2023	BUY	$30.02 - $38.81 $19.2 Million - $24.8 Million	638,676 Added 134.29%	1,114,287 $36.6 Million
Q2 2023 Aug 14, 2023	SELL	$26.7 - $37.02 $13.2 Million - $18.3 Million	-494,029 Reduced 50.95%	475,611 $16.8 Million
Q1 2023 May 15, 2023	BUY	$26.64 - $39.74 $7.99 Million - $11.9 Million	299,950 Added 44.79%	969,640 $27.5 Million
Q4 2022 Feb 14, 2023	BUY	$38.78 - $46.78 $18 Million - $21.8 Million	465,055 Added 227.26%	669,690 $27.8 Million
Q3 2022 Nov 14, 2022	SELL	$30.9 - $50.65 $3.28 Million - $5.38 Million	-106,248 Reduced 34.18%	204,635 $8.48 Million

Others Institutions Holding PRCT

# of Institutions

300

Shares Held

42M

Call Options Held

223K

Put Options Held

165K

View Full List

About PROCEPT BioRobotics Corp

Ticker PRCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 44,592,300
Market Cap $3.01B
Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...

More about PRCT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account